Asimadolin (EMD-61753) je lek koji deluje kao periferni selektivni agonistκ-opioidnog receptora.[4][5] Zbog njegove neznatne sposobnosti prolaska kroz krvno moždanu barijeru, asimadolin ne ispoljava psihotomimetičke efekte centralno delujućih kapa agonista, i konsekventno ima veći potencijal za medicinsku upotrebu. On je bio testiran kao mogući treatman upalnu bolest creva, i utvrđeno je da je relativno efikasan.[6][7]
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
↑Barber A, Gottschlich R (October 1997). „Novel developments with selective, non-peptidic kappa-opioid receptor agonists”. Expert Opinion on Investigational Drugs6 (10): 1351–68. DOI:10.1517/13543784.6.10.1351. PMID15989506.
↑Delvaux M, Beck A, Jacob J, Bouzamondo H, Weber FT, Frexinos J (July 2004). „Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome”. Alimentary Pharmacology & Therapeutics20 (2): 237–46. DOI:10.1111/j.1365-2036.2004.01922.x. PMID15233705.